Slayback Pharmaceuticals
About Slayback Pharmaceuticals
Slayback Pharmaceuticals is a company based in West Windsor Township (United States) founded in 2011 was acquired by Azurity Pharmaceuticals in September 2023. Slayback Pharmaceuticals has raised $110 million across 2 funding rounds from investors including KKR, Everstone Capital and Azurity Pharmaceuticals. Slayback Pharmaceuticals offers products and services including XIFYRM and FIRVANQ.
- Headquarter West Windsor Township, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Azurity Pharmaceuticals, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$110 M (USD)
in 2 rounds
-
Latest Funding Round
$50 M (USD), Series B
Jan 06, 2020
-
Investors
KKR
& 2 more
-
Employee Count
Not available
-
Acquired by
Azurity Pharmaceuticals
(Sep 01, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Slayback Pharmaceuticals
Slayback Pharmaceuticals offers a comprehensive portfolio of products and services, including XIFYRM and FIRVANQ.
XIFYRM is utilized for the management of moderate-to-severe pain in adults as an IV non-steroidal anti-inflammatory drug.
FIRVANQ is employed as an anti-infective treatment in various therapeutic contexts.
People of Slayback Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Slayback Pharmaceuticals
Slayback Pharmaceuticals has successfully raised a total of $110M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Slayback Pharmaceuticals
Slayback Pharmaceuticals has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include KKR, Everstone Capital and Azurity Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in mid-market businesses linked to India and Southeast Asia.
|
Locked | Locked | Locked | |
|
Multiple sectors are invested in by this private equity firm.
|
Locked | Locked | Locked | |
|
Generic drugs are manufactured by Azurity Pharmaceuticals in the US.
|
Locked | Locked | Locked |
Investor details for Slayback Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Slayback Pharmaceuticals
Investment portfolio details for Slayback Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Slayback Pharmaceuticals
Detailed financials for Slayback Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Slayback Pharmaceuticals Comparisons
Peer comparison for Slayback Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Slayback Pharmaceuticals
Detailed competitors of Slayback Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Slayback Pharmaceuticals
Complete news archive for Slayback Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Slayback Pharmaceuticals
Slayback Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Slayback Pharmaceuticals is headquartered in West Windsor Township, United States. It is registered at West Windsor Township, New Jersey, United States.
Slayback Pharmaceuticals is a funded company, having raised a total of $110M across 2 funding rounds to date.
Slayback Pharmaceuticals was founded in 2011 and is based in West Windsor Township, United States. Operations center on the pharmaceutical sector, producing specialty generics through complex formulations including sterile injectables, emulsions, suspensions, microspheres, topical products, foams, aerosols, controlled substances with advanced delivery, and high-bioavailability oral products. FDA approval has been secured for a generic acyclovir ointment targeting herpes infections in specific patient groups.
Slayback Pharmaceuticals offers XIFYRM and FIRVANQ.
Slayback Pharmaceuticals has 3 investors. Key investors include KKR, Everstone Capital, and Azurity Pharmaceuticals.